Vertex Pharmaceuticals Incorporated logo

Vertex Pharmaceuticals Incorporated

VRTX
HealthcareNASDAQUnited States
446.39USD-4.85 (-1.07%)

About Vertex

Vertex Pharmaceuticals Incorporated is a biotechnology company focused on developing and commercializing therapies for serious diseases, with a core focus on cystic fibrosis (CF).

  • Cystic Fibrosis: TRIKAFTA (for CF patients aged 6+ with at least one F508del mutation), SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO (target specific CFTR gene mutations)

  • Pipeline Therapies:

    • AAT Deficiency: VX-864 (Phase 2)

    • Kidney Diseases: VX-147 for APOL1-mediated FSGS and related kidney conditions (Phase 2)

    • Type 1 Diabetes: VX-880 (Phase 1/2)

    • Pain Management: VX-548, a NaV1.8 inhibitor for acute, neuropathic, and musculoskeletal pain (Phase 2)

    • Sickle Cell Disease and Beta-Thalassemia: CTX001 (Phase 3, in collaboration with CRISPR Therapeutics)

The company primarily sells its products to specialty pharmacies and distributors in the U.S., and to hospitals, clinics, and retail chains internationally.

Collaborations: Vertex partners with Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem.

Vertex was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex's Business Strategy

Vertex operates with a focused innovation strategy, specializing in developing transformative medicines for serious diseases with significant unmet needs. The company has established market dominance in cystic fibrosis (CF) through a series of increasingly effective CFTR modulator therapies that address the underlying cause of the…

Available on Finplify

Free account required

Sign up free

Our Take on Vertex

Pros:

Leader in Cystic Fibrosis (CF): Vertex has dominant global market share in CF treatment, with its portfolio of CFTR modulators (including Trikafta/Kaftrio) addressing the vast majority of CF patients. Vertex’s CF treatments are highly effective, used long-term by patients, and face little competition,…

Available on Finplify

Free account required

Sign up free

Company Details

Exchange
NASDAQ
Country
United States
Sector
Healthcare
Industry
Biotechnology
CEO
Reshma Kewalramani
Employees
6,100
IPO Date
1991-07-24
ISIN
US92532F1003
Website
vrtx.com

Key Metrics

Market Cap
113.38BUSD
P/E Ratio (TTM)
28.98
Net Profit Margin
32.84%
Debt / Asset Ratio
0.15
Dividend Yield (TTM)
0.00%
Volume
132,342
Avg Volume
1.46M
Shares Outstanding
256.39M
Free Float
98.62%
β Beta
0.32
52W Range
362.5 - 514.0

Fundamental Analysis

Proprietary 5-category scoring system

Score Fingerprint

Section Scores

Profitability
4.8/5Excellent
Liquidity
5.0/5Excellent
Leverage
5.0/5Excellent
Cash Flow
4.0/5Good
Valuation
3.9/5Good

Full Breakdown & Peer Ranking

See the detailed score for every metric and how this stock ranks against its sector peers

Unlock for free
Free to join

Unlock the full research on Vertex

Get the full fundamental score breakdown, business strategy, our investment take, live charts and AI-powered briefings. All in one ad-free workspace.

300+ Curated Stocks

A hand-picked universe of world-class businesses across every major market and sector.

AI Analyst Briefings

Deploy your own AI analyst that monitors your portfolio and delivers daily intelligence reports.

Proprietary Fundamentals

Five-category scoring for every stock — profitability, liquidity, leverage, cash flow, and valuation.